Ulusoy 2010.

Methods	Study design: parallel RCT Duration of study: not reported Follow‐up: 12 months ADPKD assessment: Echo
Participants	Country: Turkey Setting: single centre Stage 1–2 hypertensive ADPKD patients (according to the JNC VII classification); eGFR > 30 mL/min/1.73 m2; aged 18 to 70 years Number: treatment group (19); control group (13) Mean age ± SD (years): treatment group (51 ± 10); control group (48 ± 13) Sex (M/F): treatment group (6/13); control group (7/6) Exclusion criteria: other kidney illness or comorbidity, including DM; CHF; liver function failure; pregnancy, lactation; using anti‐arrhythmic; oral contraceptive use; immunosuppressive and steroid use; psychiatric disorders
Interventions	Treatment group Losartan: 50 to 100 mg/d Control group Ramipril: 2.5 to 10 mg/d Duration of intervention 12 months
Outcomes	BP LVMI Kidney function
Notes	Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Insufficient information to permit judgement